Mindray Medical International Debuts Three New SFDA Approved Products at the 57th China International Medical Equipment Fair

SHENZHEN, China, April 9 /Xinhua-PRNewswire-FirstCall/ -- Mindray Medical International Limited (NYSE: MR) today announced it will exhibit three newly released products including the BS-400, a fully automated biochemistry analyzer, the MR-96A, an enzyme-linked analyzer, and the MW-12A, a micro plate washer, at the 57th China International Medical Equipment Fair in Dalian, China from April 10-13, 2007.

"These three SFDA approved diagnostic instruments are high-quality additions to our portfolio of diagnostic laboratory instruments and we expect to see substantial demand for them in both the rapidly growing China market as well as other international markets," said Mr. Xu Hang, Mindray's Chairman and Co-Chief Executive Officer. "In particular, the BS-400 represents a milestone for our company and for China, as it is the first biochemistry analyzer of its speed and grade produced by a Chinese company."

The BS-400 allows clinical laboratories to increase the speed at which samples are analyzed, and has greater capacity to store sample data. With a sample tray that can host 90 samples and 77 analytical reagents simultaneously, and an automatic barcode scanning technique for samples and reagents, the BS-400 outperforms its counterparts, the BS-200 and BS-300. Combined with a comparative cost advantage, these features will allow Mindray to target China's tier two hospitals, the largest market segment for medical equipment sales in China, and other markets in both developing and developed countries.

"The speed and functionality of the BS-400 at competitive pricing reflects successful sustained efforts by our research and development teams to tailor our product development towards targeted new markets," added Mr. Xu Hang.

The MR-96A enzyme-linked analyzer and the MW-12A plate washer are integral instruments employed in the examination of HBV-M, HBV, HIV, and tumors using a process called Enzyme-Linked ImmunoSorbent Assay, or "ELISA". These two instruments will help Mindray further penetrate the in-vitro immunologic diagnosis equipment segment.

"With our focus on delivering a competitive price performance ratio, Mindray is well positioned to capture greater market share both domestically and abroad," said Mr. Li Xiting, Mindray's President and Co-Chief Executive Officer.

About Mindray

Mindray Medical International Limited is a leading developer, manufacturer and marketer of medical devices in China with a significant and growing presence worldwide. Established in 1991, Mindray offers a broad range of products across three primary business segments: patient monitoring devices, diagnostic laboratory instruments, and ultrasound imaging systems. Mindray is headquartered in Shenzhen, China, and has 29 local sales and services offices in China, as well as sales and services offices in Boston, Istanbul, London, Mumbai, Seattle and Vancouver. For more information, please visit .

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Statements that are not historical facts, including statements about Mindray's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Information regarding these risks and uncertainties is included in our registration statement on Form F-1 and other documents filed with the Securities and Exchange Commission. Mindray does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this press release is as of April 9, 2007, and Mindray undertakes no duty to update such information, except as required under applicable law.

For further information, please contact:

In China:

Investor Relations

Mindray Medical International Limited

Tel: +86-755-2658-2518


Justin Knapp

Ogilvy Public Relations Worldwide, Beijing

Tel: +86-10-8520-6556


In U.S.:

Jeremy Bridgman

Ogilvy Public Relations Worldwide, New York

Tel: +1-212-880-5269

Source: Mindray Medical International Limited